Pipeline

Clinical Pipeline


Shattuck’s lead partnered compound entered the clinic in April 2019, and its lead wholly-owned compound will enter the clinic in the second half of 2020.

To date, Shattuck’s Agonist Redirected Checkpoint (ARC) platform has yielded more than 300 bi-functional fusion protein drug candidates, two of which are currently in clinical trials for the treatment of life-threatening and debilitating diseases. The three lead ARC molecules are designed to block checkpoint molecules that limit the immune system (PD-1, CD47, and CSF1R) while simultaneously stimulating T-cell receptors to initiate an immune response (OX40 or CD40). Shattuck’s lead partnered asset, SL-279252 (PD1-Fc-OX40L), has advanced to the clinic in less than two years and is currently enrolling patients at five sites across the United States, Canada, and Europe. Shattuck’s internal lead asset, SL-172154 (SIRPα-Fc-CD40L), will be enrolling patients in its clinical trials during the second half of 2020.

ProgramDiscoveryPreclinicalPhase 1Phase 2Phase 3Status
SL-279252
PD1-Fc-OX40L

Enrolling Phase 1 / Data Expected Late 2021

SL-172154 - I.V.
SIRPα-Fc-CD40L

Phase 1 Study Open

SL-172154 - I.T.I.
SIRPα-Fc-CD40L

Phase 1 Study Open

SL-115154
CSF1R-Fc-CD40L

Expected IND Second Half 2021

Wholly Owned
Partnered
DrugIndicationStage
SL-279252 PD1-Fc-OX40L Phase 1
SL-172154 - I.V.SIRPα-Fc-CD40L Preclinical
SL-172154 - I.T.I.SIRPα-Fc-CD40L Preclinical
SL-115154 CSF1R-Fc-CD40L Preclinical

Discovery and Preclinical Pipeline


With over 300 bi-functional fusion protein compounds created to date, Shattuck has a robust pipeline of therapeutic candidates for the treatment of cancer and autoimmune disease.

ProgramDiscoveryLead SelectionNon-Clinical DevelopmentManufacturingStatus
R&D ONCOLOGY
SL-279137
PD1-Fc-41BBL

IND-enabling Studies

SL-279258
PD1-Fc-LIGHT

Nonclinical Development

SL-172258
SIRPα-Fc-LIGHT

Nonclinical Development

SL-VS9258
TIGIT-Fc-LIGHT

IND-enabling Studies

SL-086159
CD86-Fc-NKG2a

Nonclinical Development

Multiple
Multiple Undisclosed

Nonclinical Development

R&D AUTOIMMUNE
Multiple
Multiple Undisclosed

Nonclinical Development

Wholly Owned
Partnered
DrugIndicationStage
R&D ONCOLOGY
SL-279137PD1-Fc-41BBL Non-Clinical Development
SL-279258PD1-Fc-LIGHT Manufacturing
SL-172258SIRPα-Fc-LIGHT Manufacturing
SL-VS9258TIGIT-Fc-LIGHT Non-Clinical Development
SL-086159CD86-Fc-NKG2a Lead Selection
MultipleMultiple Undisclosed Lead Selection
R&D AUTOIMMUNE
MultipleMultiple Undisclosed Lead Selection